Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q1 2024 Earnings Presentation
12 slides from Angiodynamics's earnings presentation, Oct 4, 2023
Slide 1: First Quarter 2024 Earnings Presentation
AngioDynamics First Quarter 2024 Earnings Presentation October 4, 2023
Slide 2: Forward-Looking Statement
AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future fi
Slide 3: Corporate Developments – Q1 FY24
IDE Clinical Studies and Pathway Expansion Corporate Developments – Q1 FY24 AngioDynamics First Quarter 2024 Earnings 3 Divested the Dialysis and BioSentry tract sealant system businesses for $100.0 million $50.1 million of proceeds used to extinguish outstanding debt U.S. District Court for the Dis
Slide 4: Q1 FY24 Results (unaudited)
Q1 FY24 Results (unaudited) AngioDynamics First Quarter 2024 Earnings 4 $ in thousands (except per share data) Q1 FY24 As Reported Q1 FY23 As Reported Change Q1 FY24 Pro-Forma Q1 FY23 Pro-Forma Change Revenue $78,679 $81,537 (3.5%) $78,008 $73,791 5.7% Med Tech Med Device $25,860 $52,819 $22,817 $58
Slide 5: Q1 FY24 Results (pro-forma)
Q1 FY24 Results (pro-forma) 5 Med Device Med Tech 13.3% growth 2.3% growth Q1 Revenue Growth Q1 FY23 Q1 FY24 Q1 Revenue Contribution Q1 FY23 Q1 FY24 Med Tech Gross Margin 64.7% Med Device Gross Margin 43.9% AngioDynamics First Quarter 2024 Earnings
Slide 6: Sales Comparison to Prior-Year Period
Sales Comparison to Prior-Year Period AngioDynamics First Quarter 2024 Earnings 6 Med Tech Q1 FY24 Auryon 25.7% Thrombus Management* AngioVac AlphaVac (6.7%) (7.7%) 1.8% NanoKnife® Disposables 34.5% NanoKnife® Capital 41.4% Med Device Q1 FY24 Core Peripheral (0.4%) Venous (5.8%) PICCs (9.9%) Midline
Slide 7: FY24 Guidance Reaffirmed
FY24 Guidance Reaffirmed 7 * FY23 pro-forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share of $0.43. AngioDynamics First Quarter 2024 Earnings Guidance* Revenue $328 - $333 million Gross Margin Med Tech Med Device 50.0% - 52.
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 9: Reconciliation of GAAP to Non-GAAP Pro Forma Results
9 Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousands, except per share data) (in thousands) Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Slide 10: Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS Reconciliation of Net Income (Loss) to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items
Slide 11: Reconciliation of Non-GAAP Pro Forma Net Income (Loss)
Reconciliation of Non-GAAP Pro Forma Net Income (Loss) to Adjusted Pro Forma Net Loss and EPS Reconciliation of Non-GAAP Pro Forma Net Income (Loss) to Adjusted Pro Forma EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairment
Slide 12: Thank You
Thank You AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate, or a subsidiary. All other trademarks are property of their respective owners. © 2023 AngioDynamics, Inc.